| | Business Summary | | Trimeris,
Inc.
is
engaged
in
the
discovery
and
development
of
a
class
of
antiviral
therapeutics
called
viral
fusion
inhibitors
(FIs).
The
Company's
most
advanced
product
candidates,
T-20
and
T-1249,
are
for
the
treatment
of
human
immunodeficiency
virus,
type
I
or
HIV.
T-20
is
a
first-generation
FI
that
prevents
HIV
from
entering
and
infecting
cells.
T-1249
is
a
rationally
designed
second-generation
FI
in
an
earlier
stage
of
development.
Through
its
study
and
knowledge
of
the
HIV
fusion
process,
the
Company
has
developed
a
proprietary
technology
platform
aimed
at
discovering
compounds
that
identify
potential
fusion
targets
in
certain
viruses
that
rely
on
fusion
to
penetrate
host
cells.
Using
its
proprietary
viral
fusion
platform
technology,
the
Company
has
identified
and
filed
patent
applications
disclosing
numerous
discrete
peptide
sequences
that
appear
to
inhibit
fusion
for
several
viruses. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | TRMS,
is
a
biopharmaceutical
company
engaged
in
the
discovery
and
development
of
novel
therapeutic
agents
that
block
viral
infection
by
inhibiting
viral
fusion
with
host
cells.
TRMS's
main
product,
T-20,
inhibits
fusion
of
HIV
with
host
cells.
For
the
six
months
ended
6/30/01,
revenues
rose
55%
to
$652
thousand.
Net
loss
before
accounting
change
rose
12%
to
$30.2
million.
Results
reflect
higher
payments
from
Roche,
offset
by
increased
R&D
expenses. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Jeffrey Lipton, 58
Chairman | -- | -- | Dani Bolognesi, Ph.D., 60
CEO,
Chief Scientific Officer | $448K | $731K | Robert Bonczek, 56
CFO,
Gen. Counsel | 319K | -- | M. Nixon Ellis, Ph.D., 51
Exec.
VP, CBO | 329K | -- | M. Kang, Ph.D., 49
Sr.
VP of Devel. | -- | -- | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/t/trms.gif)